Aurinia Pharmaceuticals (AUPH) Expected to Announce Earnings on Thursday

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP is projected to announce its Q2 2025 earnings results before the market opens on Thursday, July 31st. Analysts expect the company to announce earnings of $0.18 per share and revenue of $64.27 million for the quarter. Aurinia Pharmaceuticals has set its FY 2025 guidance at EPS.

Aurinia Pharmaceuticals (NASDAQ:AUPH - Get Free Report) TSE: AUP last announced its quarterly earnings data on Monday, May 12th. The biotechnology company reported $0.16 earnings per share for the quarter, beating analysts' consensus estimates of $0.08 by $0.08. The company had revenue of $62.47 million for the quarter, compared to analyst estimates of $61.06 million. Aurinia Pharmaceuticals had a return on equity of 14.27% and a net margin of 16.11%. On average, analysts expect Aurinia Pharmaceuticals to post $0 EPS for the current fiscal year and $1 EPS for the next fiscal year.

Aurinia Pharmaceuticals Price Performance

Shares of NASDAQ:AUPH traded down $0.14 during trading on Friday, hitting $8.93. 1,232,970 shares of the stock were exchanged, compared to its average volume of 2,036,506. The company has a fifty day moving average price of $8.24 and a two-hundred day moving average price of $8.08. The company has a market cap of $1.21 billion, a PE ratio of 31.89 and a beta of 1.16. The company has a current ratio of 5.93, a quick ratio of 5.26 and a debt-to-equity ratio of 0.16. Aurinia Pharmaceuticals has a 12-month low of $5.20 and a 12-month high of $10.67.

Institutional Investors Weigh In On Aurinia Pharmaceuticals

Several institutional investors have recently modified their holdings of AUPH. Royal Bank of Canada raised its position in shares of Aurinia Pharmaceuticals by 65.3% during the 1st quarter. Royal Bank of Canada now owns 367,661 shares of the biotechnology company's stock worth $2,956,000 after purchasing an additional 145,179 shares during the last quarter. AQR Capital Management LLC raised its position in shares of Aurinia Pharmaceuticals by 8.7% during the 1st quarter. AQR Capital Management LLC now owns 503,543 shares of the biotechnology company's stock worth $4,048,000 after purchasing an additional 40,380 shares during the last quarter. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its position in shares of Aurinia Pharmaceuticals by 4.6% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 79,811 shares of the biotechnology company's stock worth $642,000 after purchasing an additional 3,497 shares during the last quarter. Hedge funds and other institutional investors own 36.83% of the company's stock.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.